innovaTV 301 / ENGOT cx12

About this trial

This trial is to demonstrate improvement in clinical efficacy of tisotumab vedotin compared to chemotherapy in subjects with 2L-3L cervical cancer.

Patient Profile

Ages Eligible for Study: 18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study: Female
Accepts Healthy Volunteers: No

Patients with recurrent/metastatic cervical cancer
(r/mCC) who have received 1 or 2 prior lines of chemotherapy

Where’s this trial being run?

University Hospital Waterford

Can I join this study / trial?

The first thing you do is to talk to your doctor and/or the cancer trials research team in your hospital. The contact details for the cancer trials research units in Ireland is here.

Why not Print this page and bring it with you. It will help your doctor and research team advise you.

For more detailed information

Questions?

Here’s a list of questions you may have for your doctor or local cancer research team.


Summary Data

Name: innovaTV 301 / ENGOT cx12
Number: 19-02
Full Title:

A Randomized, Open-Label, Phase 3 Trial of Tisotumab Vedotin vs Investigator’s Choice Chemotherapy in Second or Third-Line Recurrent or Metastatic Cervical Cancer

Principal Investigator: Dr Paula Calvert
Type: Industry Sponsored
Sponsor:

Seagen Inc.

Recruitment Started: Global: February 2021
Ireland: November 2022
Global Recruitment Target: 486
Ireland Recruitment Target: 20